Diabetes

The citation from the World Economic Forum allows the digital behavioral health company to participate in the annual meeting of new champions.Some will also participate in the annual meeting in Davos, Switzerland.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

Coverage from Patient-Centered Diabetes Care, April 7-8, 2016. Presented by The American Journal of Managed Care and Joslin Diabetes Center.

For African Americans in poor Mississippi counties, having diabetes and kidney disease in combination lead to cardiovascular death rates that were on par with underdeveloped nations.

A report developed by Avalere Health, based on a survey that the company conducted among health plans in 2015, states that a majority of health plans want to sign outcomes-based contracts with biopharmaceutical companies, especially for oncology and hepatitis C drugs.

The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.

The American Journal of Managed Care presents two new installments in its multistakeholder Peer Exchange video series. The first addresses screening and treatment for diabetic macular edema, and the second discusses several important new studies on optimal treatment in type 2 diabetes, including cardiovascular outcomes of empagliflozin.

A new nursing-driven diabetes education process established within a patient-centered primary care model significantly improved diabetes control for veterans at the Albany Stratton VA Medical Center.

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

Researchers at the John Hopkins Bloomberg School of Public Health found that increases in unemployment in California during the Great Recession were associated with an increased risk for weight gain among 1.7 million public school children in the state.

This week, the top stories in managed care included study results presented at the 76th Scientific Sessions of the American Diabetes Association from the SWITCH and LEADER trials, a recommendation for a smarter way to screen for prostate cancer, and researchers found physicians underutilize medications to treat opioid addiction.

The partnership will allow Medtronic to scale Canary Health's diabetes prevention programs to reach a wider audience and bring Canary's self-management platform into customer support for its devices.

An analysis of claims from over 90,000 patients with type 2 diabetes (T2D) demonstrates that increased medication cost sharing is associated with higher rates of hospitalization and increased plan costs.

The diabetes advocacy community has long sought Medicare coverage for continuous glucose monitoring (CGM) systems, but the technology has been deemed "precautionary." Abstracts presented at last week's ADA Scientific Sessions could help build a case for updating FDA's clearance to use CGM for dosing, removing a hurdle to Medicare coverage.

The pair of studies evaluating the technology were presented at the American Diabetes Association and simultaneously published in the Journal of Diabetes Science and Technology.

Reseachers are studying whether drugs that have been approved for treating type 2 diabetes can be used in combination with insulin to avoid both variablity in blood glucose and weight gain.

A packed session greeted the highly anticipated results of the LEADER trial, which found that the GLP-1 receptor agonist liraglutide has cardiovascular benefits in high-risk patients with diabetes.

Data from CDC consistently show that low-income, minority groups are at higher risk for diabetes, for genetic but especially for environmental reasons.

Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.

Vitamin D may help reduce the risk of diabetes side effects associated with atypical antipsychotics, according to a recent study published in Scientific Reports.